Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series

Author(s): Julian Norman Kenyon, Richard James Fuller.

Journal Name: Current Drug Therapy

Volume 6 , Issue 1 , 2011

Become EABM
Become Reviewer

Abstract:

Sonodynamic Photodynamic Therapy (SPDT) is a novel cancer treatment approach using a photosensitive agent (Sonnelux-1) with reported ultrasound-activated properties. The sensitiser is administered prior to a cycle of light and low-intensity ultrasound exposure. Ultrasound has the advantage of significantly greater tissue penetrance compared to light, which potentially allows non-invasive activation of the sensitiser within deep-sited tumours. Sonnelux-1 has previously demonstrated significant tumour cell inhibition following ultrasound administration in animal studies, and several case reviews have been published reporting clinical benefits in metastatic cancer patients. This current case series presents outcome measures of five patients with a variety of cancer diagnoses following SPDT, providing further evidence of beneficial treatment outcomes.

Keywords: Sonodynamic therapy, photodynamic therapy, immunoediting, cancer, ultrasound, photosensitiser, malignant pathologies, tetra pyrrole, porphyrin ring, energy, molecular oxygen, cell necrosis, cytotoxicity, absorption, tissues, physiotherapy, safety, tumour growth, death, wavelengths, histology, Oncology, lymph nodes, T cell, lymphocyte division, radiotherapy, chemotherapy, photooxidative cytotoxic, neutrophilia, OZONE, AUTOHAEMOTHERAPY, TUMOUR HYPOXIA, infusion, oestrogen, progesterone, receptor, chest infections, X Ray, biopsy

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 6
ISSUE: 1
Year: 2011
Page: [12 - 16]
Pages: 5
DOI: 10.2174/157488511794079059

Article Metrics

PDF: 10